Active, not recruitingPHASE1, PHASE2NCT04305054
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
Studying Neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Pembrolizumab(biological)
- Enrollment
- 315 target
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2020 – 2026
Study locations (30)
- The Angeles Clinic and Research Institute ( Site 2009), Los Angeles, California, United States
- UCLA Hematology & Oncology ( Site 2004), Los Angeles, California, United States
- Providence Saint John's Health Center ( Site 2010), Santa Monica, California, United States
- University of Colorado, Anschutz Cancer Pavilion ( Site 2012), Aurora, Colorado, United States
- University of Florida College of Medicine-UF Health Cancer Center/Clinical Trials Office ( Site 2026), Gainesville, Florida, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 2022), Baltimore, Maryland, United States
- R.J. Zuckerberg Cancer Center ( Site 2032), Lake Success, New York, United States
- NYU Clinical Cancer Center ( Site 2002), New York, New York, United States
- Duke Cancer Institute ( Site 2005), Durham, North Carolina, United States
- Martha Morehouse Tower ( Site 2020), Columbus, Ohio, United States
- Oregon Health & Science University ( Site 2013), Portland, Oregon, United States
- University of Pennsylvania Abramson Cancer Center ( Site 2008), Philadelphia, Pennsylvania, United States
- West Cancer Center - East Campus ( Site 2014), Germantown, Tennessee, United States
- Mays Cancer Center ( Site 2025), San Antonio, Texas, United States
- Inova Schar Cancer Institute ( Site 2011), Fairfax, Virginia, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04305054 on ClinicalTrials.govOther trials for Neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06406465A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and ToxicityNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06202066Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasRoswell Park Cancer Institute
- RECRUITINGPHASE1NCT07224425A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it HelpsBoehringer Ingelheim
- RECRUITINGPHASE2NCT07449754Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaHanmi Pharmaceutical Company Limited
- RECRUITINGPHASE2NCT07336147Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical CarcinomaChang Gung Memorial Hospital
- RECRUITINGPHASE1NCT07086105A Study to Evaluate Adze1.C in Participants With Metastatic MelanomaAdze Biotechnology Australia Pty Ltd
- RECRUITINGPHASE2NCT07357623Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine TumorsShanghai Chest Hospital
- RECRUITINGPHASE2NCT07215182[68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in CancerBarbara Malene Fischer